Variations in Serum Copper and Ceruloplasmin Levels in Advanced Gastrointestinal Cancer Treated with Polychemotherapy
Variations in Serum Copper and Ceruloplasmin Levels in Advanced Gastrointestinal Cancer Treated with Polychemotherapy
复制标题
联合化疗治疗晚期胃肠癌血清铜和铜蓝蛋白水平的变化
作者：
A. Scanni;M. Tomirotti;L. Licciardello;E. Annibali;M. Biraghi;M. Trovato;M. Fittipaldi;Paola Adamoli;Guglielmo Curtarelli
对57例进展期胃癌(35例)和大肠癌(22例)联合化疗患者的血清铜和铜蓝蛋白(SCL、SCEL)水平进行了研究。在胃肠癌中，SCL在未经治疗的患者中已经很高，在疾病进展的情况下有进一步增加的趋势，而在缓解的情况下似乎显著下降。试验期间的SCEL似乎只在胃癌的病例中与疾病的临床演变相关。在大肠癌中，SCEL与正常范围相比没有显示出任何显著的变化。这些观察，特别是对消化道肿瘤中SCL行为的观察，与其他研究的结果是一致的。作者倾向于认为SCL和SCEL在胃肠道肿瘤中的变化具有诊断和预后价值。
Serum copper and ceruloplasmin levels (SCL, SCeL) in 57 patients with advanced cancer of the stomach (35 cases) or large intestine (22 cases) treated with polychemotherapy were studies. In gastroenteric cancer, SCL, which are already high in untreated patients, have a tendency to increase further in cases of progression of the disease, while they seem to significantly decrease in cases of remission. SCeL during the trial appeared to be correlated to the clinical evolution of the disease only in the case of stomach cancer. In large intestine cancer, SCeL did not show any significant variation in relation to the normal range. These observations, in particular on the behavior of SCL in the neoplasms of the digestive tract, are in accordance with the results of other studies. The authors are inclined to attach a diagnostic and prognostic value to the variation in SCL and SCeL in gastrointestinal cancer.